Curr Probl Cardiol. 2014 Mar;39(3):59-76. doi: 10.1016/j.cpcardiol.2013.11.004. Epub 2013 Nov 11.
Ischemic strokes will make up most (>80%) of the three-quarters of a million strokes that will occur in Americans this year. Reperfusion therapy is the fundamental strategy for the treatment of acute ischemic stroke. Reperfusion therapy may be accomplished noninvasively (intravenous thrombolysis) or invasively with catheter-based treatments (intra-arterial thrombolysis, thrombectomy, or angioplasty). Currently, a large majority of patients with acute ischemic stroke do not receive any form of reperfusion therapy owing to their delayed presentation (>3 hours) and lack of skilled man power for on-demand endovascular treatment. Paradoxically, improved success rates for reperfusion have been reported with the newer thrombectomy catheters, called "stentreivers." An option for broadening access for patients who need endovascular therapy would be to use interventional cardiologists with carotid stent experience who can help to provide 24 × 7 × 365 coverage.
缺血性中风将占今年美国发生的 75 万中风病例中的四分之三（>80%）。再灌注治疗是治疗急性缺血性中风的基本策略。再灌注治疗可以非侵入性（静脉溶栓）或侵入性地进行，包括导管治疗（动脉内溶栓、血栓切除术或血管成形术）。目前，由于大多数急性缺血性中风患者的就诊时间延迟（>3 小时），并且缺乏按需进行血管内治疗的熟练人力，因此大多数患者未接受任何形式的再灌注治疗。矛盾的是，新型血栓切除术导管（称为“取栓支架”）报告的再灌注成功率有所提高。为需要血管内治疗的患者扩大治疗途径的一种选择是使用有颈动脉支架经验的介入心脏病专家，他们可以帮助提供 24×7×365 的覆盖。
